Many issues need to be addressed before determining the roles of the CYP4A11-mediated 20-HETE and CYP2E1-related 19-HETE in steatosis, steatohepatitis, cirrhosis, and HCC, and possible therapeutic targets in the treatment of CLD. The gene discussed is CYP4A11; the disease is hepatocellular carcinoma.